Checkpoint inhibitors, against molecules such as PD-1, CTLA4, TIM-3, and LAG-3 have shown promise as single agents in a number of cancer types (100) but unfortunately, none of these treatment as a single therapy has generated significant clinical benefit in pancreatic cancers. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.